Breast cancer is the most common cancer among women worldwide, which is a disease in which breast cells grow out of control. Breast cancer is the second leading cause of cancer […]
Triple negative breast adenocarcinoma (triple negative breast cancer (TNBC) is a breast cancer with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2). With unique […]
On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (Nerlynx, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer to […]